文献速递糖尿病

西格列汀改善使用MiniMed 780G高级混合闭环系统的1型糖尿病青少年的血糖控制和早期糖尿病肾病:一项随机对照试验

The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.
PubMed 文献 · Diabetologia · 2024-09-14

在埃及Ain Shams大学儿童糖尿病诊所开展开放标签平行组随机对照试验,46名使用MiniMed 780G系统且伴微量白蛋白尿的1型糖尿病青少年随机分为西格列汀50 mg口服3个月组和仅AHCL对照组。3个月后西格列汀组UACR从7.27±2.41降至1.32±0.31 mg/mmol(p<0.001),SDF-1从3.58±0.73降至1.99±0.76 ng/ml(p<0.001),且安全性良好。

要点

  • 西格列汀50 mg口服3个月使UACR从7.27±2.41降至1.32±0.31 mg/mmol(p<0.001)。
  • 西格列汀使SDF-1从3.58±0.73降至1.99±0.76 ng/ml(p<0.001)。
  • 西格列汀未发生严重低血糖或糖尿病酮症酸中毒,安全且耐受良好。

核心结论

  • 西格列汀作为AHCL的附加治疗对1型糖尿病合并糖尿病肾病患者具有肾脏保护作用,同时改善目标范围内时间、降低血糖变异性且不损害安全性。

研究设计与样本

  • 开放标签、平行组随机对照试验,在埃及Ain Shams大学儿童糖尿病诊所开展。
  • 纳入46名年龄14.13±2.43岁、使用MiniMed 780G系统至少6个月、HbA1c≤69 mmol/mol(8.5%)且伴微量白蛋白尿的1型糖尿病青少年,按计算机生成随机序列分为两组(每组n=23)。
  • 干预组口服西格列汀50 mg治疗3个月,另一组仅使用AHCL作为对照组。
  • 主要结局为西格列汀给药3个月后尿白蛋白/肌酐比值(UACR)的变化,关键次要结局为治疗后SDF-1水平较基线的变化。

主要发现

  • 两组基线临床和实验室特征及AHCL系统设置无显著差异(p>0.05)。
  • 所有1型糖尿病患者血清SDF-1水平高于健康对照个体(p<0.001)。
  • 3个月后西格列汀组SDF-1从3.58±0.73降至1.99±0.76 ng/ml(p<0.001),UACR从7.27±2.41降至1.32±0.31 mg/mmol(p<0.001)。
  • 西格列汀降低餐后血糖、传感器血糖、变异系数和每日胰岛素总剂量,同时目标范围内时间3.9-10.0 mmol/l(70-180 mg/dl)和胰岛素/碳水化合物比显著增加。
  • 西格列汀安全且耐受良好,未发生严重低血糖或糖尿病酮症酸中毒。

临床怎么用

  • 作者认为,西格列汀作为AHCL的附加治疗对1型糖尿病合并糖尿病肾病患者具有肾脏保护作用,并改善目标范围内时间、降低血糖变异性且不损害安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Dipeptidyl peptidase-4 (DPP-4) inhibition has beneficial effects on various metabolic indicators in diabetes. Stromal cell-derived factor-1 (SDF-1) is expressed in diverse organs including the kidneys and is cleaved and inactivated by DPP-4 enzyme. The aim of this study was to conduct a randomised controlled trial to assess the effect of sitagliptin on diabetic nephropathy when used as an add-on therapy to the advanced hybrid closed-loop (AHCL) system in adolescents with type 1 diabetes and nephropathy. METHODS: This open-label, parallel-group, randomised controlled trial took place at the Pediatric Diabetes Clinic, Ain Shams University, Egypt. Forty-six adolescents aged 14.13 ± 2.43 years on the MiniMed 780G system for at least 6 months before study, with HbA1c ≤69 mmol/mol (8.5%) and diabetic nephropathy in the form of microalbuminuria, were randomly assigned to two groups (n=23 for each) based on a computer-generated randomisation sequence. The intervention group received oral sitagliptin 50 mg for 3 months. The other group used AHCL only and served as a control group. The primary outcome measure was the change in urinary albumin/creatinine ratio (UACR) after 3 months of administration of sitagliptin. The key secondary outcome measure was the change from baseline in SDF-1 levels after treatment. RESULTS: Data for all participants were analysed. No significant difference was found between the groups as regards baseline clinical and laboratory characteristics as well as AHCL system settings (p>0.05). Serum SDF-1 levels were higher in all individuals with type 1 diabetes vs healthy control individuals (p<0.001). After 3 months, sitagliptin resulted in a significant decrease of SDF-1 levels from 3.58 ± 0.73 to 1.99 ± 0.76 ng/ml (p<0.001), together with improvement of UACR from 7.27 ± 2.41 to 1.32 ± 0.31 mg/mmol (p<0.001). In addition, sitagliptin reduced postprandial glucose, sensor glucose, coefficient of variation and total daily dose of insulin, while time in range 3.9-10.0 mmol/l (70-180 mg/dl) and insulin-to-carbohydrate ratio were significantly increased. Sitagliptin was safe and well-tolerated without severe hypoglycaemia or diabetic ketoacidosis. CONCLUSIONS/INTERPRETATION: Sitagliptin as an add-on therapy to AHCL had a reno-protective effect for individuals with type 1 diabetes and diabetic nephropathy, in addition to the improvement of time in range while reducing glycaemic variability and without compromising safety. FUNDING: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. TRIAL REGISTRATION: ClinicalTrials.gov NCT06115460.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Elbarbary NS, Ismail EA, El-Hamamsy MH, et al. The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial. Diabetologia. 2024. PMID: 39271520. doi:10.1007/s00125-024-06265-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。